New hope for aggressive breast cancer: personalized therapy shows promise

NCT ID NCT02810743

Ongoing Disease control Sponsor: The Netherlands Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase III trial tests whether personalized therapy can improve survival for people with high-risk BRCA1-like breast cancer. Participants receive either standard chemotherapy or a more intense regimen with stem cell rescue. The study aims to find a better way to treat this aggressive cancer type.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ddAC-CP-Olaparib and ddAC-mini CTC chemotherapy with stem cell rescue
What this could lead to: If successful, this could offer a more effective, personalized treatment for high-risk BRCA1-like breast cancer, potentially improving survival rates.
What could go wrong: This is a phase III trial but with only 174 participants, results may not apply to all patients. The intensified chemotherapy carries significant risks, including side effects from stem cell rescue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

AZVU

Amsterdam, 1081 HV, Netherlands
Antoni van Leeuwenhoek

Amsterdam, 1066 CX, Netherlands
Erasmus Medical Center Cancer Institute

Rotterdam, 3015CE, Netherlands
Hopital Tenon, University Marie-Curie

Paris, France
Institut Paoli Calmettes

Marseille, 13009, France
LUMC

Leiden, 2333 ZA, Netherlands
Maastricht University Medical Center

Maastricht, Netherlands
Medical spectrum Twente

Enschede, Overijssel, 7500 KA, Netherlands
Radboud UMC

Nijmegen, 6225GA, Netherlands
University Medical Center Groningen

Groningen, Netherlands
University Medical Center Utrecht

Utrecht, 3584CX, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.